Nebido



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 50.0%
Drug Use For Unknown Indication 22.2%
Hypogonadism Male 11.1%
Azoospermia 5.6%
Hypogonadism 5.6%
Klinefelter's Syndrome 5.6%
Low Density Lipoprotein Increased 20.0%
Aspermia 10.0%
Dyspnoea 10.0%
Epilepsy 10.0%
Extraocular Muscle Paresis 10.0%
Hyperhidrosis 10.0%
Musculoskeletal Chest Pain 10.0%
Prostate Cancer 10.0%
Vith Nerve Paralysis 10.0%
Secondary
Product Used For Unknown Indication 41.4%
Androgen Deficiency 16.1%
Hypogonadism 8.0%
Drug Use For Unknown Indication 6.9%
Hypertension 6.9%
Blood Testosterone Decreased 4.6%
Hypopituitarism 3.4%
Type 2 Diabetes Mellitus 3.4%
Blood Cholesterol Increased 2.3%
Osteoarthritis 2.3%
Erectile Dysfunction 1.1%
Hyperlipidaemia 1.1%
Hyperuricaemia 1.1%
Hypogonadism Male 1.1%
Hyperhidrosis 25.0%
Product Quality Issue 20.0%
Asthenia 10.0%
Thyroid Cyst 10.0%
Androgen Deficiency 5.0%
Completed Suicide 5.0%
Diffuse Large B-cell Lymphoma 5.0%
Dyspnoea 5.0%
Musculoskeletal Disorder 5.0%
Myocardial Infarction 5.0%
Rash 5.0%
Concomitant
Blood Follicle Stimulating Hormone Decreased 12.1%
Blood Luteinising Hormone Decreased 11.3%
Hypogonadism Male 7.4%
Product Used For Unknown Indication 6.5%
Hypopituitarism 6.3%
Primary Hypothyroidism 6.1%
Hypogonadism 5.6%
Blood Thyroid Stimulating Hormone Decreased 5.2%
Blood Corticotrophin Decreased 4.9%
Depression 3.9%
Hypertension 3.9%
Growth Hormone Deficiency 3.8%
Luteinising Hormone Deficiency 3.5%
Follicle-stimulating Hormone Deficiency 3.4%
Essential Hypertension 3.3%
Testicular Hypogonadism 3.2%
Diabetes Mellitus 3.0%
Acth Decreased 2.9%
Vitamin D Deficiency 1.9%
Hypothyroidism 1.8%
Death 17.1%
Arthropathy 11.4%
Pyrexia 8.6%
Prostate Cancer 6.7%
Ascites 5.7%
Meningioma 5.7%
Road Traffic Accident 5.7%
Cardiac Disorder 3.8%
Rectal Cancer 3.8%
Abscess 2.9%
Atrial Fibrillation 2.9%
Balance Disorder 2.9%
Bladder Disorder 2.9%
Chondrosarcoma 2.9%
Chondrosarcoma Recurrent 2.9%
Furuncle 2.9%
Hypertension 2.9%
Injection Site Pain 2.9%
Intestinal Haemorrhage 2.9%
Lung Adenocarcinoma 2.9%